Search Results - "Riedhammer C"

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma.

Authors: Vega G Morillo D Riedhammer C et al.

Source: HemaSphere [Hemasphere] 2026 Jun 07; Vol. 10 (6), pp. e70396. Date of Electronic Publication: 2026 Jun 07 (Print Publication: 2026).

Publication Type: Letter

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms.

Authors: Zhou X Mersi J Riedhammer C et al.

Source: Therapeutic advances in hematology [Ther Adv Hematol] 2026 Feb 28; Vol. 17, pp. 20406207261421841. Date of Electronic Publication: 2026 Feb 28 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Sage Country of Publication: England NLM ID: 101549589 Publication Model: eCollection Cited Medium: Print ISSN: 2040-6207 (Print) Linking ISSN: 20406207 NLM ISO Abbreviation: Ther Adv Hematol Subsets: PubMed not MEDLINE

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Authors: Zhang, Lili Bangolo, Ayrton Amoozgar, Behzad et al.

Source: Cancers. Jun2026, Vol. 18 Issue 12, p1996. 13p.

Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.

Authors: Youssef, Nagham Hameed, Maha Atrash, Shebli et al.

Source: Current Oncology. Jun2026, Vol. 33 Issue 6, p355. 16p.

Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.

Authors: Waldschmidt JM Haug L Riedhammer C et al.

Source: Frontiers in oncology [Front Oncol] 2025 Jan 16; Vol. 14, pp. 1518775. Date of Electronic Publication: 2025 Jan 16 (Print Publication: 2024).

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Real-world incidence of severe infections in multiple myeloma patients receiving bispecific antibodies: a meta-analysis.

Authors: Spataro F Desantis V Einsele H et al.

Source: Annals of hematology [Ann Hematol] 2026 Apr 27; Vol. 105 (5). Date of Electronic Publication: 2026 Apr 27.

Publication Type: Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

Single‐cell RNA sequencing and high‐dimensional flow cytometry reveal distinct peripheral immune landscapes of type 1 autoimmune pancreatitis and pancreatic ductal adenocarcinoma.

Authors: Liu, Chenxiao Che, Tianyi Liu, Airu et al.

Source: Clinical & Translational Medicine. Apr2026, Vol. 16 Issue 4, p1-22. 22p.

Serological pseudoprogression of multiple myeloma after treatment with teclistamab.

Authors: Daunov, Michael Alagha, Ibrahim Rashidi, Arash et al.

Source: Leukemia & Lymphoma. Apr2026, Vol. 67 Issue 5, p1160-1163. 4p.

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Authors: Riedhammer C Truger M Lee H et al.

Source: Leukemia [Leukemia] 2026 Apr; Vol. 40 (4), pp. 730-738. Date of Electronic Publication: 2026 Feb 17.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Authors: Corona M García-Vicente R Saez-Marin AJ et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Mar 06; Vol. 14 (3). Date of Electronic Publication: 2026 Mar 06.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

Authors: Lee H Ahn S Gonzales GA et al.

Source: Nature medicine [Nat Med] 2026 Mar; Vol. 32 (3), pp. 964-977. Date of Electronic Publication: 2026 Jan 15.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.

Authors: Hartung, Hans-Peter Robertson, Derrick Steinman, Lawrence et al.

Source: Neurology & Therapy. Jun2026, Vol. 15 Issue 3, p1081-1097. 17p.

Analyzing Real-World Infection Risk in Multiple Myeloma Patients Receiving Teclistamab.

Authors: Ssentongo, Paddy Guare, Emma G. Song, Chen et al.

Source: Current Oncology. Mar2026, Vol. 31 Issue 3, p154. 12p.

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.

Authors: Varma, Gaurav Fogel, Lindsay Gordon, Beth et al.

Source: Leukemia & Lymphoma. May2025, Vol. 66 Issue 5, p942-951. 10p.

Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review.

Authors: Bandaru, Sai Samyuktha Multani, Naveen Singh Nauam, William Thomas et al.

Source: Case Reports in Oncology. Sep2024, Vol. 17 Issue 1, p1063-1069. 7p. 5 Illustrations.

Melflufen in Multiple Myeloma: Clinical Limitations, Biological Rationale, and Future Perspectives.

Authors: Garibotto, Matteo Soncini, Debora Lemoli, Roberto Massimo et al.

Source: Cancers. May2026, Vol. 18 Issue 10, p1551. 15p.

Clinical characteristics and prognostic analysis of concurrent Pneumocystis jirovecii pneumonia in patients with malignancies: a retrospective study.

Authors: Shi, Yujie Chen, Ruxuan Xu, Kai et al.

Source: BMC Infectious Diseases. 10/27/2025, Vol. 25 Issue 1, p1-8. 8p.

Immunophenotyping and Functional Characterization of NK Cells in SARS-CoV-2 Infection.

Authors: Petrov, Steliyan Bozhkova, Martina Ivanovska, Mariya et al.

Source: Immuno. Sep2025, Vol. 5 Issue 3, p35. 21p.

Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab.

Authors: Mudawi, Deena Al-Mashdali, Abdulrahman F. Tawalbeh, Ahmad et al.

Source: Case Reports in Oncology. 2025, Vol. 18 Issue 1, p628-637. 10p.

Multiple myeloma in 2026 — current guidelines and new therapies.

Authors: Charliński, Grzegorz Vesole, David H. Jurczyszyn, Artur

Source: Nowotwory. 2026, Vol. 76 Issue 2, p108-127. 20p.